Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sawai Pharmaceutical Co., Ltd.

https://www.sawai.co.jp/en/

Latest From Sawai Pharmaceutical Co., Ltd.

Keppra And Velcade Rivals Among Sawai’s New Listings

Rivals to Careram, Keppra, Patanol, Velcade and Volibris have been listed with Japan’s NHI drug price list by Sawai, as the company seeks to capitalize on its position as a leading supplier in the market.

Launches Generic Drugs

Sawai To Take Over Facilities Owned By Scandal-Hit Kobayashi Kako

Kobayashi Kako has agreed to transfer ownership of eight of its production, research and distribution facilities to Sawai, which will use them to expand the manufacturing of its own generics. Business was suspended at Kobayashi Kako for 116 days this year after the company’s manufacturing deficiencies were linked to two deaths.

Deals Generic Drugs

Sawai Maintains Strong Domestic Performance, Continues To Flounder In US

Sawai’s Q2 results mirrored those of Q1, with a strong performance in Japan but a weak one in the US. The firm is continuing to focus on establishing new production facilities in both territories.

Sales & Earnings Strategy

Can Sun’s Novel Partnered Topical Drug Alter Acne Options?

Sun-Cassiopea’s novel mechanism of action acne drug sees a “fair degree” of early physician interest in the US, with some analysts expecting the topical androgen receptor inhibitor to emerge as a key addition to the Indian’s firm’s specialty portfolio.

Commercial Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
  • Other Names / Subsidiaries
    • Cambridge Biotechnology Ltd (CBT)
    • Minster Pharmaceuticals
    • Proximagen Group
    • Upsher-Smith Laboratories Inc.
    • Medisa Shinyaku Inc. and Kaken Shoyaku Inc.
UsernamePublicRestriction

Register